Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning. Today, we meet Pfizer’s new chief scientific officer, ponder why the stock for Silence Therapeutics dropped despite promising data, and see that pharma executives aren’t too worried about Robert F. Kennedy, Jr.
The need-to-know this morning
- Argenx said it will advance a subcutaneously injected form of its drug Vyvgart into Phase 3 studies for the treatment of myositis, an autoimmune disease that attacks muscles. The decision was based on positive results from a mid-stage study.
- AI drug developer Recursion Pharmaceuticals closed its merger with Exscientia.
- Sage Therapeutics said it is discontinuing the development of SAGE-718, the only remaining drug in its clinical research pipeline, following negative results from a study to treat cognitive impairment in patients with Huntington’s disease.
- Hoth Therapeutics bought up to $1 million in bitcoin as a treasury reserve asset.
Pfizer named a new Chief Scientific Officer
Pfizer on Wednesday promoted its Chief Oncology Officer Chris Boshoff to head all R&D at the company, STAT’s Matthew Herper writes. Boshoff is taking over for Mikael Dolsten, who served as chief scientific officer for 15 years and announced his retirement in July.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
